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Abstract
The most common cause of death in menopausal women is due to complications
from cardiovascular disease. However, many physicians feel that the prevention
in women may be delayed, because women present the clinical manifestations
of cardiovascular disease 10 years later than men. Another matter emerged
following the results of the Women’s Health Initiative study and of the Heart
Estrogen/Progestin Replacement Study. Thus the proper interpretation and
implementation of science should be included in a strict procedure of
appreciation and clear communication for both the qualitative and quantitative
evaluation of evidence, used for the clinical guidelines. Based on objective
scientific collaboration among various specialities, guidelines for the prevention
of cardiovascular disease of adult women with a broad range of cardiovascular
risk have been formed. In this review, the guidelines or recommendations which
have been reported in the last 2 decades by various scientific societies for
prevention of cardiovascular disease in women will be analysed.
Key words: women, coronary artery disease, premenopausal, postmenopausal,
hormone replacement therapy.
Introduction
The most common cause of death in menopausal women is due to
complications from cardiovascular (CV) disease and the most severe
complication of CV disease is sudden death. In the Framingham Heart Study
[1-4], it was found that 2/3 of women who died suddenly had been
asymptomatic before. No wonder that these circumstances lead medical
societies to suggest more intensive primary and secondary prevention in
women [5]. However, many physicians feel that the prevention in women can
be delayed, because women present the clinical manifestations of CV disease
10 years later than men. Another matter emerged following the results of
the Women’s Health Initiative study [6, 7] and of the Heart Estrogen/Progestin
Replacement Study (HERS) [7]. Both studies unexpectedly reported an
association between combined hormone replacement therapy (HRT) and
increased CV events [8-11]. This required a critical review and strategy based
on documented evidence for prevention of CV disease in women. The proper
interpretation and implementation of science with the aim of improving
preventive care should be included in a strict procedure of appreciation and
clear communication for both the qualitative and quantitative evaluation of
evidence used for the clinical guidelines. Moreover, all existing evidence,
including that for men, should be involved after modification for the
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Copyright © 2011 Termedia & Banachformulation of the guidelines for women. Additionally,
many patients do not share a similar clinical profile
to patients participating in clinical trials; thus the
conclusions should be drawn regarding the potential
similarities, and genera  lization from basic research
to clinical practice.
Based on objective scientific collaboration among
various specialities, guidelines for prevention of CV
disease of adult women with a broad range of CV risk
have been formed. 
Also, after 2 decades of applying the most
sophisticated techniques for the diagnosis of CV
disease in its early stages, the classification as primary
and secondary prevention has become less important.
Instead, the grading of CV risk and identification of
a high risk group have become more significant.
The guidelines do not represent obligatory rules,
but aim at updating physicians’ knowledge regarding
the severe problem that every aging wo  man is going
to face, and its prompt implemen  tation. Below, the
guidelines or suggestions which have been reported
in the last 2 decades by various scientific societies for
prevention of CV disease in women will be analysed.
American Heart Association Scientific
Statement ‘Cardiovascular Disease in Women’
In 1997 the American Heart Association (AHA)
published ‘Cardiovascular Disease in Women’ [5]. In
this statement the role of major risk factors (RFs),
preceding CV disease, such as smoking, arterial
hypertension (including isolated systolic hyper  -
tension), dyslipidaemia, diabetes mellitus, obesity,
sedentary life style, and unhealthy diet, has been
emphasized [5]. Smoking was considered to be the
first reversible RF and responsible for > 50% of
myocardial infarctions (MI) in middle aged women
[12]. Moreover, it was emphasised that CV RFs which
are manifested in women have different frequency
and their reduction is often less intense than in men.
For example, the rate of reduction of smoking is lower
in women than in men. The incidence of obesity
increases more often in aging women than in aging
men. Also, more than 52% of women aged above 45
years old present an elevated blood pressure, and
more than 40% of women aged above 55 years old
present elevated blood cholesterol levels [5].
However, as far as primary prevention is
concerned, pharmacotherapy has been recom  -
mended only for the high risk group of patients, and
a change of lifestyle, such as cessation of smoking,
regular physical activity, maintenance of a normal
body weight, and consumption of a diet containing
low unsaturated fatty acids and intake of increased
amounts of fruits and vegetables, has been stressed.
Concerning secondary prevention after MI,
physicians should consult the guidelines, published
in 1995 and 1996, for the management of patients
with acute MI [13-16]. According to these guidelines
the administration of β-blockers, inhibitors of
angiotensin-converting enzyme (ACE) (when the left
ventricular ejection fraction is < 40%), aspirin and
lipid-lowering drugs was recommended. The
administration of calcium channel blockers,
antiarrhythmic drugs, or magnesium, has not been
recommended as a routine therapy during the
occurrence of an MI or later.
Concerning secondary prevention after stroke, the
guidelines have recommended only the admi  -
nistration of aspirin. Moreover, according to this
statement, the administration of HRT in post  -
menopausal women has been recommended on an
individualized basis. 
AHA/ACC Scientific Statement: Consensus Panel
Statement
The first guidelines regarding the prevention of
cardiac disease in women were published in 1999 by
the American Heart Association (AHA)/American
College of Cardiology (ACC) Scientific Statement:
Consensus Panel Statement [17, 18]. Until then, the
medical community had not paid great attention to
RFs in women. In the HERS study [7], only 10% of
participating women presented desirable low density
lipoprotein (LDL) cholesterol levels, according to the
guidelines of the National Cholesterol Education
Program (NCEP) [19, 20]. Moreover, women had fewer
possibilities to participate in a rehabilitation
programme, after an MI, leading to less intensive
treatment. However, in 1995 and 1997, the
recommendations for primary and secondary
prevention of coronary heart disease, which could be
applied to women, were published (see above).
There is an exceptional aspect of women’s RFs.
This advantage of women had not been mentioned
before in any guidelines. Pregnancy and the life period
before pregnancy represent the most favourable
period of a woman’s life for reviewing the RFs and
lifestyle, in order to limit the future CV morbidity. The
cessation of smoking in pregnant women should be
recommended to be continued also after the delivery.
The prevention of excess increase of body weight
during pregnancy may reduce the risk of occurrence
of future events of CV disease. The prevention in
women should be emphasized since it is essential,
having in mind that CV disease in women increases
with age. 
In those guidelines, the administration of HRT in
perimenopausal and postmenopausal women for the
prevention of CV disease, osteoporosis, or possible
dementia was also a decision that physicians should
make. In particular, physicians should consider the
potential favourable effects of HRT and underlying
complications of these drugs, including breast cancer,
uterus cancer, thromboembolic episodes and diseases
of the gallbladder.
Furthermore, the guidelines emphasized that the
regulation of RFs preceding CV disease, such as
diabetes mellitus and other RFs (abnormal lipid profile
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and/or arterial hypertension), plays an essential role
in reducing CV events. For example, low plasma high
density lipoprotein (HDL) cholesterol level in women
aged > 65 years is considered to be more important
for the prediction of CV disease than in men at the
same age [21]. At that time, the guidelines of the
NCEP (ATP II, 1994) [22] stressed the imperative need
for more aggressive management of low HDL
cholesterol and elevated triglyceride levels in women.
In the same guidelines, a recommendation for
administration of HRT to postmenopausal women for
the regulation of increased LDL cholesterol was
introduced [22]. If LDL cholesterol levels remained
elevated, a recommendation for administration of
a lipid-lowering drug, and in particular statin
(inhibitors of HMG CoA reductase), was introduced.
Nowadays, this recommendation has been modified
(see below), and administration of statins in
postmenopausal women represents a first line choice,
with the same favourable results as in men.
Evidence-Based Guidelines for Cardiovascular
Disease Prevention in Women 
In 2004, the guidelines (Evidence-Based
Guidelines for Cardiovascular Disease Prevention
in Women) were published by the Experts Com  -
mittee, with Mosca being the first author [23, 24].
A great effort has been made in order to create
evidence-based guidelines. In these guidelines,
women were classified in groups, depending on risk
level (high, moderate, low, and favourable). As
a high risk group (Framingham global risk (10-year
CV risk) > 20%) were classified women who have
been diagnosed with coronary heart disease, stroke,
peripheral artery disease, abdominal aortic
aneurysm, diabetes mellitus or chronic renal failure.
As a moderate risk group (Framingham global risk
10-20%) were classified women with subclinical CV
disease (coronary artery calcification) or metabolic
syndrome or multiple RFs or one significantly
elevated RF, or who have 1st degree relatives with
early CV disease (< 55 years in men and < 65 years
in women). As a low risk group (Framingham global
risk < 10%) were classified women who have only
one or no RF, while women with optimal levels of
RFs and heart healthy lifestyle should be cha  -
racterised as a favourable risk group (Framingham
global risk < 10%).
Also, it should be noted that the Expert
Committee has classified for the first time the
clinical recommendations, depending on evidence.
Evidence was classified (Table I) according to the
type of study and its primary endpoints (death, MI,
stroke, revascularization procedures (angioplasty or
aortocoronary bypass) and heart failure or some
combination of them). Finally, the Expert Committee
formulated the clinical guidelines for women 
(Tables II and III) [23, 24].
The diet recommended by the Experts
Committee concerned healthy nutrition. The Experts
Committee has concluded that the consumption of
fish is correlated with the reduction of risk for CV
disease. However, women of reproductive age, and
particularly pregnant women, should avoid the
consumption of fish such as shark, swordfish, chub
mackerel, common mackerel, and finally, white cod,
because those fish contain high amounts of
mercury, and may affect the normal growth of the
nervous system of the fetus. Pregnant women are
allowed to consume fish such as salmon and sole.
For the management of classical RFs, the Experts
Committee has referred physicians to the guidelines
of Scientific Associations, respectively the National
Cholesterol Education Program Adult Treatment
Panel III [19], the Seventh Report of the Joint
National Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressure
[25], and the American Diabetes Association [26].
Concerning the treatment of high blood
pressure, in hypertensive patients, women and
men, lowering blood pressure causes a significant
reduction of CV events. Treatment with thiazide
diuretics is recommended as a first line therapy
while  β-blockers are not prescribed now as
a common antihypertensive therapy in patients
with no complications [25].
ClassificationS t rength of recommendation
Class
I  Intervention is useful and effective
IIa Evidence is in favour of usefulness 
and efficacy
IIb Usefulness and efficacy are less 
established
III Intervention is not useful and may be 
harmful
Level of evidence
A Adequate confirmation from 
multicentre, randomised trials
B Limited evidence derived from a single
randomised, or non-randomised trial
C Based on opinions of experts, 
case reports, or implemented care
Generalizability index
1 Great probability for the results to be 
extended also to women
2 It is possible that results can be 
extended also to women
3 It is unlikely the results can be 
extended also to women
0 The extension to women cannot be 
confirmed
Table I. Classification of evidence levels [23, 24]750 Arch Med Sci 5, October / 2011
Clinical recommendations Class, level, 
generalizability 
index
Lifestyle interventions
Cigarette smoking: consistently encourage women to avoid smoking, active or passive I, B, 1
Physical activity: consistently encourage women to perform exercise of moderate intensity,  I, B, 1
for 30 min (brisk walking), on most days of the week, preferably on all days of the week
Cardiac rehabilitation: women, after an acute coronary event, or an intervention in coronary arteries,  I, B, 2
or with chronic angina pectoris, should participate in a comprehensive risk reduction regimen such 
as cardiac rehabilitation programme, or should implement the instructions of the physician at home, 
or should participate in a community programme
Heart healthy diet: constant encouragement to follow a healthy diet, e.g. consumption of a variety  I, B, 1
of fruits, vegetables, cereals, dairy products with low or without fat, consumption of fish, legumes, 
and proteins with low content of unsaturated fat (poultry, lean meat, plant). Restriction of consumption 
of unsaturated fat (< 10% of total calories), cholesterol (300 mg/daily), and trans-fatty acids
Weight maintenance or reduction: constant encouragement of maintenance of body weight or  I, B, 1
reduction, a proper balance between physical activity and caloric uptake, and, if necessary, 
implementation of a regular programme, for a body weight index of 18.5 kg/m2 to 24.9 kg/m2
and a waist circumference < 88 cm to be maintained/accomplished
Psychosocial factors: women with CV disease should be evaluated for potential depression,  IIa, B, 2
and should be reported or cured when there are indications
Ω-3 fatty acids: these substances may be administered in high risk women, in the form of diet  IIb, B, 2
supplements
Folic acid: it may be administered in high risk women, as a diet supplement, if homocysteine levels  IIb, B, 2
are high
Major RF intervention
Arterial hypertension – lifestyle: encouragement to maintain a favourable blood pressure level  I, B, 1
of < 120/80 mmHg, during all lifetime
Arterial pressure – drugs: pharmacotherapy is indicated when arterial pressure is > 140/90 mmHg,  I, A, 1
or lower, in combination with damage of target organ, influenced by hypertension. Thiazide diuretics 
should be one of the drugs if there are no contraindications
Lipids, lipoproteins: women’s favourable levels are < 100 mg/dl for LDL cholesterol, > 50 mg/dl  I, B, 1
for HDL cholesterol, < 150 mg/dl for triglycerides, and < 130 mg/dl for non-HDL cholesterol 
(total cholesterol – HDL cholesterol). Lifestyle change should be encouraged
Lipids – dietary therapy: consumption of saturated fat should be reduced to < 7% of total calories,  I, B, 1
and cholesterol to 200 mg daily, in high risk women, or with elevated plasma LDL cholesterol levels. 
Consumption of trans-fat should also be reduced
Lipids – pharmacotherapy – high risk: initiation of LDL lowering treatment (statins preferred),  I, A, 1
along with lifestyle change, in high risk women, and LDL cholesterol ≥ 100 mg/dl. 
Initiation of treatment with statins for LDL lowering in high-risk women, and LDL cholesterol  I, B, 1
< 100 mg/dl, unless contraindicated. Initiation of treatment with nicotinic acid or fibrates when 
HDL cholesterol is low or non-HDL cholesterol is elevated I, B, 1
Lipids – pharmacotherapy – moderate risk: iInitiation of LDL lowering treatment (statins preferred),  I, A, 1
along with lifestyle change, when LDL cholesterol is ≥ 130 mg/dl. Nicotinic acid or fibrates when 
HDL cholesterol is low, or non-HDL cholesterol is high, after the target LDL cholesterol level has been  I, B, 1
accomplished
Lipids – pharmacotherapy – low risk: initiation of LDL lowering treatment in women with 0-1 RFs  IIa, B
and LDL cholesterol ≥ 190 mg/dl, or multiple RFs and LDL cholesterol ≥ 160 mg/dl. Nicotinic acid 
or fibrates when HDL cholesterol is low, or non-HDL cholesterol is high, after the target  IIa, B, 1
LDL cholesterol level has been accomplished
Diabetes mellitus: lifestyle change and pharmacotherapy for HbA1c level (haemoglobulin adult 1c)   I, B, 1
< 7% to be accomplished
Table II. Clinical recommendations, for lfestyle and major RFs intervention, in women [23, 24]
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In addition, the Experts Committee has formed
guidelines for the prevention of stroke in women who
developed chronic or paroxysmal atrial fibrillation
(Table IV).
The Experts Committee has also established the
priority in prevention of CV disease in women,
depending on risk group classification. In the high risk
group (risk < 20%), the following have been proposed
as class I recommendations: smoking cessation,
physical activity or cardiac rehabilitation, dietary
treatment, maintenance or reduction of body weight
when necessary, arterial pressure control, lipid control
or statin therapy, aspirin therapy, β-blocker therapy,
ACE inhibitor therapy (AT1 inhibitors when ACE
inhibitors are contraindicated) and diabetes control.
Also recommended in the same group are the
evaluation or treatment of depression and the
administration of Ω-3 fatty acids and folic acid as class
IIa and class IIb respectively. A class I recommendation
dictates that the moderate risk women group (risk
10-20%) should stop smoking, should be familiar with
physical activity or cardiac rehabilitation, and maintain
body weight or reduce it when necessary. In addition,
the same group should be encouraged to follow
dietary treatment and treatment of every RF according
to the guidelines, whereas according to the class IIa
recommendation, these women are advised to follow
an aspirin therapy regimen. Moreover, in the low risk
group (risk < 10%), smoking cessation, physical activity
or cardiac rehabilitation, dietary treatment,
maintenance or reduction of body weight and the
proper regulation of every RF for heart disease are
rated as class I recommendations. Finally, concerning
stroke prevention in women with atrial fibrillation, in
the high or moderate risk group it was recommended
to receive treatment with coumarin, whereas the low
risk group (< 1%) or women with contra  indications
for administration of coumarin regimen should be
treated with aspirin according to a class I recom  -
mendation.
For the first time these guidelines clarified if
patients should be prescribed HRT. Based on recent
studies, HRT has been recommended as class III,
level A. This conservative management of post  meno  -
pausal women is recommended, until new data from
clinical studies would emerge. The Experts Committee
concluded that administration of hormone
replacement for the amelioration of symptoms or for
osteoporosis concerns other scientific organizations.
Recommendations from the U.S. Preventive
Services Task Force (USPSTF)
In 2005 the recommendations from the U.S.
Preventive Services Task Force (USPSTF) were
published [27]. The USPSTF categorized its recom  -
mendations according to one of five classi  fications
depending on level of evidence. If the USPSTF strongly
recommends physicians to provide the re  com  -
mendations to eligible patients and has found enough
evidence, proving the benefits, then this re  com  -
mendation is classified as class A. When the USPSTF
Recommendations Class, level, 
generalizability 
index
Aspirin – high risk: administration of aspirin (75-162 mg daily) or clopidogrel,  I, A, 1
if there is a contraindication for aspirin, in high-risk women, unless contraindicated
Aspirin-moderate risk: administration of aspirin (75-162 mg daily) in moderate risk women,  IIa, B, 2
provided that blood pressure has been adequately controlled, and its favourable effect exceeds 
the probability of bleeding from the gastrointestinal system
β-Blockers: these drugs should be administered indefinitely in all women with a history of myocardial  I, A, 1
infarction, or with chronic myocardial ischaemia, unless contraindicated
ACE inhibitors: these drugs should be administered in high risk women, unless contraindicated I, A, 1
Angiotensin II receptor (AT1) inhibitors: these drugs should be administered in high risk women  I, B, 1
with clinically confirmed heart failure, or an ejection fraction of < 40%, who cannot tolerate ACE inhibitors
Table III. Clinical recommendations for drug interventions, in women [23, 24]
Guidelines Class, level, 
generalizability 
index
Coumarin – atrial fibrillation: in women with chronic or paroxysmal atrial fibrillation,   I, A, 1
coumarin should be administered, for INR to be maintained at a level of 2.0-3.0, unless the risk 
for a stroke is < 1%, or there is a high risk of bleeding
Aspirin – atrial fibrillation: in women with chronic or paroxysmal atrial fibrillation,  I, A, 1
aspirin can be administered, in a dose of 325 mg/daily, if there is a contraindication for administration 
of coumarin, or the risk of a stroke is < 1%
Table IV. Prevention of stroke in women with atrial fibrillation [23, 24]752 Arch Med Sci 5, October / 2011
recommends physicians to provide the recom  -
mendations to eligible patients and has found enough
evidence, proving that benefits exceed complications,
the recommendation is categorised as class B. The
class C recommendation means that the USPSTF has
found evidence proving that the benefits just
counterbalance the complications and makes no
recommendation for or against the implementation
of guidelines, while when the USPSTF recommends
against routine implemen  tation of guidelines and has
found enough evidence proving that it is not effective
and the complications exceed the benefits, the
recommendation should be characterized as class D.
Finally, the class E recommendation shows that the
USPSTF does not recommend the implementation of
guidelines, because there is no evidence concerning
either benefits or complications. In these guidelines
the main points regarded the administration of HRT 
in postmenopausal women [27]. The USPSTF
concluded that administration of a combination
consisting of oestrogens and progesterone for
management of chronic diseases in postmeno  pausal
women should not be advised in everyday practice,
as also was stated in Evidence Based Guidelines for
Cardiovascular Disease Prevention in Women. The
administration of HRT has been classified as Class D.
The USPSTF has found quite enough evidence proving
that HRT has not been effective, and potential
complications exceed the possible benefits.
The combination of oestrogens with progeste  rone
has beneficial effects on reduction of fractures [28]
and intestine cancers [29, 30], but has no effect, or
even increases, the CV, thrombo  embolic [31, 32] and
cholecystitis events [8, 33], elevates the risk of
occurrence of breast cancer [34-37], strokes [38] and
dementia [39], and finally reduces cognitive functions
[40]. The USPSTF has reported that postmenopausal
women present a possibility of having coronary heart
disease (46%), stroke (20%), hip fractures (15%),
breast cancer (10%), and uterus cancer (2.6%) [27].
Cardiovascular Diseases in Women:
a Statement from the Policy Conference 
of the European Society of Cardiology
The European Society of Cardiology in 2006
initiated the extensive programme “Women at
Heart”, aiming to coordinate the research and further
education for the prevention of CV disease in women
and particularly of coronary heart disease and strokes
[41]. The first stage of this programme was to
establish a regular conference for recording various
issues. A lot of topics have been discussed, and some
of them will be analysed below.
In 2004, the World Health Organization published
an estimation that in Europe, CV disease is
responsible for 43% of deaths in men and 55% in
women [41]. Coronary heart disease is responsible for
21% of deaths in men and for 23% in women, while
stroke is responsible for 11% of deaths in men and
18% in women. However, women have not realized
this risk [23] and still believe that breast cancer causes
more deaths.
Another topic which has been discussed at this
conference concerns the difference in response to
therapy between the two genders. For example,
aspirin administration reduces mortality from stroke,
and yet does not affect the mortality caused by MI
(in contrast to what happens in men) [42].
During this conference the tables evaluating the
probability of death in the next 10 years (SCOPE
charts) were created. Also, HRT in postmenopausal
women (not recommended for the prevention of CV
disease), the difference that exists concerning the
manifestation and management of coronary heart
disease between the two genders, the risk and
therapy of stroke in women with atrial fibrillation, and
finally the cost-benefit ratio, were analysed [41].
Evidence-Based Guidelines for Cardiovascular
Disease Prevention in Women (Updated)
In 2007, the updated clinical guidelines for 
the prevention of CV disease in women were
published (Tables V and VI) [43, 44]. Below, only the
differences between the previous guidelines will be
analysed.
The classification of women, depending on risk
level, has been partially modified in comparison with
the Evidence-Based Guidelines for Cardio  vascular
Disease Prevention in Women. Women with
documented coronary heart disease, stroke, peripheral
artery disease, abdominal aortic aneurysm, end stage
renal disease, diabetes mellitus or Framingham 
10-year global risk > 20% are classified as a high risk
group. In addition, women with one or more than one
major RF for CV disease, such as smoking, unhealthy
diet, physical inactivity, obesity and specifically central
obesity, arterial hypertension, metabolic syndrome,
dyslipidaemia and family history with an early CV
disease (< 55 years in men, and < 65 years in women)
are categorized in the moderate risk group. Also,
women who present reduced tolerance in exercise
stress testing and/or abnormal heart rate after the
test or evidence of subclinical CV disease according
to coronary artery calcification belong to the moderate
risk group. Finally, women who have a healthy
lifestyle, no RF or Framingham 10-year global risk 
> 20% should be classified in the favourable risk group.
Emphasis has been paid to the total risk (of the
whole lifetime) and not only to the next 10 years,
which is determined by the Framingham algorithm.
Aspirin administration for the prevention of CV
disease in women aged > 65 years, or for the
prevention of stroke in women aged < 65 years, is
cited in Table V.
Conclusions
The CV diseases, in spite of the significant
interventions that have been made for primary and
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secondary preventions, are still the main cause of
death in men and women of the western world 
[18, 45]. Particularly, concerning women, deaths from
CV disease, in every age group, are more prevalent
and even higher than breast cancer [46]. Furthermore,
in women, when the CV disease is revealed, the
prognosis is more threatening compared to men. In
the guidelines of the American Heart Association
(AHA Scientific Statement, Evidence-Based Guidelines
for Cardiovascular Disease Prevention in Women, see
above), Mosca et al. [23] reported that in the United
States of America, more than half a million of women
were dying from CV disease each year. The World
Health Organization (WHO) reported that women’s
deaths due to MI or stroke had a linear relationship
with age. 
The prevalence of MI in women with normal levels
of oestrogens is very low (1% to 7% per 100 000) and
3-5 times lower than in men. Some studies suggested
genetic variability [47]. However, this favourable
relationship disappears in older women (> 65 years).
The major determinant differentiating women from
men is oestrogens. Oestrogens exert various actions
on the organs of the human body, and particularly
on the female body [48-51]. Their levels vary during
the woman’s life time and influence many organs.
The results from the clinical trials, reported by
many investigators, regarding the hormone status
of women and the occurrence of CV events have
led to the conclusions that oestrogens exert
a protective effect on atherogenesis, on the
formation of atherosclerotic plaque, and sub  -
sequently on clinical manifestation of athero  -
genesis, namely CV disease. During the past years,
the management of women has detained several
scientific organizations, which have published
Management Class, level
Aspirin – high risk
Administration of aspirin (75-365 mg) if no contraindications I, A
When there is intolerance to aspirin in high risk women, clopidogrel would be administered I, B
Aspirin – other risks or healthy women IIb, B
In women aged ≥ 65 years, aspirin administration (81 or 100 mg every other day), provided there is 
adequate control of arterial pressure, and as long as the favourable effects on prevention of MI 
or stroke exceed the potential of a haemorrhage from the gastrointestinal system and cerebral arteries
β-Blockers I, A
β-Blockers should be indefinitely administered in all women with a history of MI, or with myocardial 
dysfunction, with or without symptoms of cardiac failure, if there are no contraindications
ACE inhibitors/AT1 inhibitors
The ACE inhibitors should be administered if there are no contraindications, in women with an MI  I, A
and clinical manifestations of heart failure, or with an ejection fraction ≤ 40%, or with diabetes mellitus
In women with MI and clinical manifestations of heart failure, or with an ejection fraction ≤ 40%, I,  B
or with diabetes mellitus and intolerance to ACE inhibitors, angiotensin II, AT1 receptors antagonists 
should be administered
Aldosterone antagonists  I, B
These drugs should be administered after an MI, provided there is no severe renal insufficiency, 
or hyperkalaemia, and if ACE inhibitors, β-blockers are received, an ejection fraction ≤ 40%, 
and symptoms of heart failure are presented
Table V. Clinical guidelines for women [43, 44]
Management Class, level
Treatment of menopause III, A
The HRT for selective control of ER receptors (SERMs) should not be administered for either primary 
or secondary prevention of CV disease
Antioxidative supplements  III, A
Antioxidative vitamin supplements (vitamin E, C, β-carotene) should not be administered for primary 
or secondary prevention of CV disease
Folic acid III, A
Folic acid, with or without supplements of vitamins B6 or B12, should not be administered for primary 
or secondary prevention of CV disease
Aspirin for the prevention of MI in women aged < 65 years  III, B
Daily administration of aspirin in women aged < 65 years old should not be recommended 
for prevention of myocardial infarction.
Table VI. Management of class III for the prevention of CV disease and MI in women [43, 44]754 Arch Med Sci 5, October / 2011
guidelines. These guidelines are practical and
helpful for physicians for the primary and secondary
prevention of CV disease in women of all ages.
Observational studies reported that HRT was
effective for most symptoms and diseases
(particularly CV and osteoporotic disease) of
menopausal women, and its use was recom  mended.
However, disadvantages of HRT emerged from two
large randomised controlled trials, HERS [7] and WHI
[6], that found no benefits for prevention of CV
diseases. Particularly, the WHI trial found an increase
in breast cancer incidence and in CV events in healthy
women. Later, the Million Women Study [52] showed
an increase in breast cancer incidence associated with
HRT. The publication of these findings led to different
interpretations, among researchers, specialists (mainly
gynaecologists and oncologists) and general
practitioners, of HRT’s benefits. Nowadays the use of
HRT is limited to women in the early menopause and
suffering from hard-to-bear symptoms. The HRT
should be used for the shortest possible period and
at the lowest effective doses. However, the results
from the Kronos Early Estrogen Prevention Study
(KEEPS) [53] and the Early versus Late Intervention
Trial with Estradiol (ELITE) [53] are expected. Until then,
HRT has been graded as a class III recommendation
for the prevention of CV disease in women.
More research is required to evaluate the long-
term benefits and side effects of HRT. However, there
are a few new beliefs, for example that by starting
HRT near menopause, the side effects may be
diminished (the majority of studies evaluating the
effects of HRT include women roughly 10 years after
menopause). Another significant observation was
drawn from the Women’s Health in the Lund Area
Study (3 600 postmenopausal women without HRT
and 2 816 postmenopausal treated with HRT or who
were under HRT in the past) [54]. In this study, women
who were receiving HRT had fewer risk factors for CV
disease and followed a healthier lifestyle. Also,
transdermal vaginal preparations may reduce certain
adverse effects (breast, uterus and bowel cancer,
pulmonary embolism) [55]. Additionally, low doses
and very low doses of hormones may be more
appropriate, especially in older women [56]. Until then,
HRT should be decided by the physician separately
for each woman based on symptoms, health status,
personal beliefs and expectations. The individual risk-
benefit balance is very important. 
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